Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of Diseases and Conditions Caused by Increased Vascular Permeability

Inactive Publication Date: 2015-11-26
STEMNION
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is a new treatment for diseases and conditions caused by increased vascular permeability, such as burns, physical injuries, infections, and more. The treatment involves using a solution containing proteins, cytokines, and growth factors called Amnion-derived Cellular Cytokine Solution (ACCS). This solution has been found to reduce vascular permeability in various tests and can be used to treat a wide range of diseases and conditions that result from increased vascular permeability. The invention also includes a method for administering the ACCS to patients and a method for reducing vascular permeability in a patient.

Problems solved by technology

In the absence of prompt intervention, a cytokine storm can result in permanent lung damage and, in many cases, death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Vascular Permeability Assays

[0095]Objective: TNF-α has been shown to increase endothelial monolayer permeability (Mark, K. S., et al., Life Sciences, 1999, 64(21):1941-1953)In order to test whether ACCS has the ability to affect vascular permeability, initial experiments were performed to determine whether ACCS could reduce the level of permeability of endothelial cells exposed to TNF-α.

[0096]Method: The ability of ACCS to modulate vascular permeability was evaluated using an In Vitro Vascular Permeability Assay (Millipore, Cat. No. ECM640). In this assay, Human vascular endothelial cells (HUVEC) were seeded onto collagen or fibrin-coated semi-permeable membrane inserts and a monolayer of cells was formed which occluded the membrane pores. The inserts were then placed in a receiver well. The cell monolayer can be treated with cytokines, growth factors, or other compounds of interest. In this experiment, the cells were treated with TNF-α and a high molecular weight FITC-labe...

example 2

Evaluate Whether ACCS Can Modulate Increased Vascular Permeability as a Result of Irradiation

[0098]Objective: Radiation is known to increase vascular permeability. Therefore, a second set of experiments was conducted to determine whether ACCS could modulate increased vascular permeability as a result of irradiation from a 5 Gy cesium-137 source.

[0099]Method: HUVECs were exposed to a radiation dose of 5 Gy prior to treatment with ACCS, control media, or endothelial growth media control.

[0100]Results: As shown in Table 3 below, ACCS Lot A-treated cells showed reduced FITC-Dextran fluorescence compared to endothelial growth media control, and control media. These results demonstrate that ACCS is modulating and therefore reducing vascular permeability. Table 4 shows that radiation exposure to the cells induced an increase in vascular permeability which was decreased by ACCS Lot A and Lot B compared to endothelial growth media control, and control media.

TABLE 3Endothelial GrowthMedia Con...

example 3

The Effect of ACCS on Reduction of Vascular Permeability in a Setting Wherein Radiation is Combined with TNF-α

[0101]Objective: Increased vascular permeability due to radiation may result from many stimuli in vivo. Radiation combined with inflammatory molecules may better simulate multiple inflammatory causes of permeability in vivo. To further evaluate the effect of ACCS on reduction of vascular permeability, HUVECs were exposed to both radiation and TNF-α, in various media.

[0102]Method: HUVECs were exposed to 5 Gy radiation and 50 ng / mL TNF-α for 4 hours.

[0103]Results: Both ACCS Lot A and Lot B showed reduced permeability of endothelial cells that were exposed to both 5 Gy radiation and 50 ng / mL TNF-α as compared to endothelial growth media control and control media.

TABLE 5ACCSACCSEndothelialControlLot ALot BGrowthMedia(fluor-(fluor-Media Control(fluor-escence)escence)(fluorescence)escence)5 Gy + 50 ng / mL8.49.325.921.8TNF-α

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Permeabilityaaaaaaaaaa
Login to View More

Abstract

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Description

FIELD OF THE INVENTION[0001]The field of the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The field of the invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the field of the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).BACKGROUND OF THE INVENTION[0002]Vascular permeability, often in the form of capillary permeability or m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/19A61K35/50A61K38/18
CPCA61K38/19A61K35/50A61K38/18A61K38/1858A61K38/1866A61K38/1891A61K38/191A61K38/57A61K2300/00
Inventor BROWN, LARRY R.BANAS, RICHARD A.WESSEL, HOWARD C.GILL, ELISE M.
Owner STEMNION